PDZ-RhoGEF Inhibitors
The chemical class of PDZ-RhoGEF Inhibitors encompasses a range of compounds that indirectly suppress the activity of PDZ-RhoGEF, a guanine nucleotide exchange factor involved in Rho GTPase signaling. These inhibitors do not directly target PDZ-RhoGEF but exert their influence through modulation of upstream pathways and mechanisms that are integral to its function. This class is characterized by its variety, including cholesterol-lowering statins, actin cytoskeleton disruptors, and specific toxins known to affect Rho GTPase activity.
Statins, including Lovastatin, Simvastatin, Atorvastatin, Mevastatin, Pravastatin, and Rosuvastatin, inhibit the mevalonate pathway, crucial for the post-translational modification of Rho GTPases. This inhibition affects the activity of Rho GTPases, which in turn can lead to the reduced activity of PDZ-RhoGEF. Compounds like Toxin B from Clostridium difficile directly target Rho GTPases, inhibiting their activity and thus potentially reducing PDZ-RhoGEF function. Latrunculin B and Cytochalasin D, known for their effects on actin polymerization, can also indirectly influence PDZ-RhoGEF by altering the actin cytoskeleton, which is closely regulated by Rho GTPase signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin, a cholesterol-lowering agent, may influence Rho GTPase signaling indirectly by altering lipid raft composition and cellular cholesterol levels, potentially leading to the inhibition of PDZ-RhoGEF. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Latrunculin B disrupts actin polymerization. By altering the actin cytoskeleton, it can indirectly affect PDZ-RhoGEF activity as PDZ-RhoGEF is involved in actin cytoskeletal regulation through Rho GTPases. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Similar to other statins, Simvastatin inhibits the mevalonate pathway and affects isoprenoid synthesis, which is necessary for Rho GTPase function. This inhibition can indirectly reduce PDZ-RhoGEF activity. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin, another statin, functions similarly by inhibiting the mevalonate pathway. Its effect on Rho GTPase signaling can indirectly lead to the inhibition of PDZ-RhoGEF. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D inhibits actin polymerization. Its influence on the cytoskeleton can indirectly affect PDZ-RhoGEF activity, which is involved in cytoskeletal regulation via Rho GTPases. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $75.00 $175.00 | 18 | |
Mevastatin inhibits HMG-CoA reductase, impacting the mevalonate pathway and subsequently Rho GTPase activity. This can lead to indirect inhibition of PDZ-RhoGEF. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $68.00 $159.00 $772.00 | 2 | |
Pravastatin, a member of the statin family, similarly inhibits the mevalonate pathway affecting Rho GTPase activity, potentially leading to PDZ-RhoGEF inhibition. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $142.00 | 8 | |
Rosuvastatin, another statin, impacts Rho GTPase activity through the mevalonate pathway, potentially resulting in PDZ-RhoGEF inhibition. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $36.00 $107.00 | 1 | |
An immunosuppressant that can affect guanine nucleotide synthesis, mycophenolate mofetil may indirectly impact Rho GTPase activity and therefore PDZ-RhoGEF function. | ||||||